Drugmakers see a pricing blueprint in an $850,000 gene therapy

SAN FRANCISCO (Reuters) - Global drugmakers are looking to a tiny biotech's $850,000 therapy for a rare type of blindness as a model for getting paid for highly expensive – and effective – new medicines.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news